Intravesical Bacillus Calmette-Guerin (BCG) Therapy for Non-muscle Invasive Bladder Cancers: Long-term Results of a Modified Schedule
Abstract Intravesical BCG therapy is an integral part of management of non-muscle invasive bladder cancers. Our aim is to analyze the non-muscle invasive bladder cancer patients treated at our center with a modified schedule intravesical BCG therapy. Data from patients treated at our center from 200...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Malik, Kanuj [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2021 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© Indian Association of Surgical Oncology 2021 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Indian Journal of Surgical Oncology - Springer-Verlag, 2010, 12(2021), 4 vom: 09. Sept., Seite 796-801 |
|---|---|
| Übergeordnetes Werk: |
volume:12 ; year:2021 ; number:4 ; day:09 ; month:09 ; pages:796-801 |
| Links: |
|---|
| DOI / URN: |
10.1007/s13193-021-01439-w |
|---|
| Katalog-ID: |
SPR045990077 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR045990077 | ||
| 003 | DE-627 | ||
| 005 | 20230507084325.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220119s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13193-021-01439-w |2 doi | |
| 035 | |a (DE-627)SPR045990077 | ||
| 035 | |a (SPR)s13193-021-01439-w-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Malik, Kanuj |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Intravesical Bacillus Calmette-Guerin (BCG) Therapy for Non-muscle Invasive Bladder Cancers: Long-term Results of a Modified Schedule |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Indian Association of Surgical Oncology 2021 | ||
| 520 | |a Abstract Intravesical BCG therapy is an integral part of management of non-muscle invasive bladder cancers. Our aim is to analyze the non-muscle invasive bladder cancer patients treated at our center with a modified schedule intravesical BCG therapy. Data from patients treated at our center from 2009 to 2017 was collected from patient records and analyzed. A 6-weekly 120-mg induction course followed by 6 monthly 120 mg has been used at our institute for NMIBC. Clinicopathological and treatment variables were collected. A total of 119 patients were treated at our center with a median follow-up period of 4.18 years with the above schedule. Nearly 96% patients were able to complete induction therapy and 79% completed the maintenance therapy. The 5-year recurrence-free survival was 83%. The recurrence and progression rates were 16.8% and 4.2% respectively. About 60% of the patients suffered from side effects of BCG with 11% having class 3 or 4 toxicity. Our regimen of monthly maintenance intravesical BCG for 6 months shows good control rates with high compliance, similar to those of other contemporary series, although with higher incidence of high-grade toxicity. | ||
| 650 | 4 | |a BCG vaccine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Clinical protocols |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Follow-up studies |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Patient compliance |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Urinary bladder neoplasm |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Raja, Anand |0 (orcid)0000-0002-2585-8527 |4 aut | |
| 700 | 1 | |a Ravishankar, Lalgudi Subramaniam |4 aut | |
| 700 | 1 | |a Narayanaswamy, Kathiresan |4 aut | |
| 700 | 1 | |a Radhakrishnan, Venkatraman |4 aut | |
| 700 | 1 | |a Sagar, Tenali Gnana |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Indian Journal of Surgical Oncology |d Springer-Verlag, 2010 |g 12(2021), 4 vom: 09. Sept., Seite 796-801 |w (DE-627)SPR030797241 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2021 |g number:4 |g day:09 |g month:09 |g pages:796-801 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13193-021-01439-w |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2021 |e 4 |b 09 |c 09 |h 796-801 | ||
| author_variant |
k m km a r ar l s r ls lsr k n kn v r vr t g s tg tgs |
|---|---|
| matchkey_str |
malikkanujrajaanandravishankarlalgudisub:2021----:nrvsclailsamteurncteayonnucenaieldecnesoge |
| hierarchy_sort_str |
2021 |
| publishDate |
2021 |
| allfields |
10.1007/s13193-021-01439-w doi (DE-627)SPR045990077 (SPR)s13193-021-01439-w-e DE-627 ger DE-627 rakwb eng Malik, Kanuj verfasserin aut Intravesical Bacillus Calmette-Guerin (BCG) Therapy for Non-muscle Invasive Bladder Cancers: Long-term Results of a Modified Schedule 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Indian Association of Surgical Oncology 2021 Abstract Intravesical BCG therapy is an integral part of management of non-muscle invasive bladder cancers. Our aim is to analyze the non-muscle invasive bladder cancer patients treated at our center with a modified schedule intravesical BCG therapy. Data from patients treated at our center from 2009 to 2017 was collected from patient records and analyzed. A 6-weekly 120-mg induction course followed by 6 monthly 120 mg has been used at our institute for NMIBC. Clinicopathological and treatment variables were collected. A total of 119 patients were treated at our center with a median follow-up period of 4.18 years with the above schedule. Nearly 96% patients were able to complete induction therapy and 79% completed the maintenance therapy. The 5-year recurrence-free survival was 83%. The recurrence and progression rates were 16.8% and 4.2% respectively. About 60% of the patients suffered from side effects of BCG with 11% having class 3 or 4 toxicity. Our regimen of monthly maintenance intravesical BCG for 6 months shows good control rates with high compliance, similar to those of other contemporary series, although with higher incidence of high-grade toxicity. BCG vaccine (dpeaa)DE-He213 Clinical protocols (dpeaa)DE-He213 Follow-up studies (dpeaa)DE-He213 Patient compliance (dpeaa)DE-He213 Urinary bladder neoplasm (dpeaa)DE-He213 Raja, Anand (orcid)0000-0002-2585-8527 aut Ravishankar, Lalgudi Subramaniam aut Narayanaswamy, Kathiresan aut Radhakrishnan, Venkatraman aut Sagar, Tenali Gnana aut Enthalten in Indian Journal of Surgical Oncology Springer-Verlag, 2010 12(2021), 4 vom: 09. Sept., Seite 796-801 (DE-627)SPR030797241 nnns volume:12 year:2021 number:4 day:09 month:09 pages:796-801 https://dx.doi.org/10.1007/s13193-021-01439-w lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 12 2021 4 09 09 796-801 |
| spelling |
10.1007/s13193-021-01439-w doi (DE-627)SPR045990077 (SPR)s13193-021-01439-w-e DE-627 ger DE-627 rakwb eng Malik, Kanuj verfasserin aut Intravesical Bacillus Calmette-Guerin (BCG) Therapy for Non-muscle Invasive Bladder Cancers: Long-term Results of a Modified Schedule 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Indian Association of Surgical Oncology 2021 Abstract Intravesical BCG therapy is an integral part of management of non-muscle invasive bladder cancers. Our aim is to analyze the non-muscle invasive bladder cancer patients treated at our center with a modified schedule intravesical BCG therapy. Data from patients treated at our center from 2009 to 2017 was collected from patient records and analyzed. A 6-weekly 120-mg induction course followed by 6 monthly 120 mg has been used at our institute for NMIBC. Clinicopathological and treatment variables were collected. A total of 119 patients were treated at our center with a median follow-up period of 4.18 years with the above schedule. Nearly 96% patients were able to complete induction therapy and 79% completed the maintenance therapy. The 5-year recurrence-free survival was 83%. The recurrence and progression rates were 16.8% and 4.2% respectively. About 60% of the patients suffered from side effects of BCG with 11% having class 3 or 4 toxicity. Our regimen of monthly maintenance intravesical BCG for 6 months shows good control rates with high compliance, similar to those of other contemporary series, although with higher incidence of high-grade toxicity. BCG vaccine (dpeaa)DE-He213 Clinical protocols (dpeaa)DE-He213 Follow-up studies (dpeaa)DE-He213 Patient compliance (dpeaa)DE-He213 Urinary bladder neoplasm (dpeaa)DE-He213 Raja, Anand (orcid)0000-0002-2585-8527 aut Ravishankar, Lalgudi Subramaniam aut Narayanaswamy, Kathiresan aut Radhakrishnan, Venkatraman aut Sagar, Tenali Gnana aut Enthalten in Indian Journal of Surgical Oncology Springer-Verlag, 2010 12(2021), 4 vom: 09. Sept., Seite 796-801 (DE-627)SPR030797241 nnns volume:12 year:2021 number:4 day:09 month:09 pages:796-801 https://dx.doi.org/10.1007/s13193-021-01439-w lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 12 2021 4 09 09 796-801 |
| allfields_unstemmed |
10.1007/s13193-021-01439-w doi (DE-627)SPR045990077 (SPR)s13193-021-01439-w-e DE-627 ger DE-627 rakwb eng Malik, Kanuj verfasserin aut Intravesical Bacillus Calmette-Guerin (BCG) Therapy for Non-muscle Invasive Bladder Cancers: Long-term Results of a Modified Schedule 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Indian Association of Surgical Oncology 2021 Abstract Intravesical BCG therapy is an integral part of management of non-muscle invasive bladder cancers. Our aim is to analyze the non-muscle invasive bladder cancer patients treated at our center with a modified schedule intravesical BCG therapy. Data from patients treated at our center from 2009 to 2017 was collected from patient records and analyzed. A 6-weekly 120-mg induction course followed by 6 monthly 120 mg has been used at our institute for NMIBC. Clinicopathological and treatment variables were collected. A total of 119 patients were treated at our center with a median follow-up period of 4.18 years with the above schedule. Nearly 96% patients were able to complete induction therapy and 79% completed the maintenance therapy. The 5-year recurrence-free survival was 83%. The recurrence and progression rates were 16.8% and 4.2% respectively. About 60% of the patients suffered from side effects of BCG with 11% having class 3 or 4 toxicity. Our regimen of monthly maintenance intravesical BCG for 6 months shows good control rates with high compliance, similar to those of other contemporary series, although with higher incidence of high-grade toxicity. BCG vaccine (dpeaa)DE-He213 Clinical protocols (dpeaa)DE-He213 Follow-up studies (dpeaa)DE-He213 Patient compliance (dpeaa)DE-He213 Urinary bladder neoplasm (dpeaa)DE-He213 Raja, Anand (orcid)0000-0002-2585-8527 aut Ravishankar, Lalgudi Subramaniam aut Narayanaswamy, Kathiresan aut Radhakrishnan, Venkatraman aut Sagar, Tenali Gnana aut Enthalten in Indian Journal of Surgical Oncology Springer-Verlag, 2010 12(2021), 4 vom: 09. Sept., Seite 796-801 (DE-627)SPR030797241 nnns volume:12 year:2021 number:4 day:09 month:09 pages:796-801 https://dx.doi.org/10.1007/s13193-021-01439-w lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 12 2021 4 09 09 796-801 |
| allfieldsGer |
10.1007/s13193-021-01439-w doi (DE-627)SPR045990077 (SPR)s13193-021-01439-w-e DE-627 ger DE-627 rakwb eng Malik, Kanuj verfasserin aut Intravesical Bacillus Calmette-Guerin (BCG) Therapy for Non-muscle Invasive Bladder Cancers: Long-term Results of a Modified Schedule 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Indian Association of Surgical Oncology 2021 Abstract Intravesical BCG therapy is an integral part of management of non-muscle invasive bladder cancers. Our aim is to analyze the non-muscle invasive bladder cancer patients treated at our center with a modified schedule intravesical BCG therapy. Data from patients treated at our center from 2009 to 2017 was collected from patient records and analyzed. A 6-weekly 120-mg induction course followed by 6 monthly 120 mg has been used at our institute for NMIBC. Clinicopathological and treatment variables were collected. A total of 119 patients were treated at our center with a median follow-up period of 4.18 years with the above schedule. Nearly 96% patients were able to complete induction therapy and 79% completed the maintenance therapy. The 5-year recurrence-free survival was 83%. The recurrence and progression rates were 16.8% and 4.2% respectively. About 60% of the patients suffered from side effects of BCG with 11% having class 3 or 4 toxicity. Our regimen of monthly maintenance intravesical BCG for 6 months shows good control rates with high compliance, similar to those of other contemporary series, although with higher incidence of high-grade toxicity. BCG vaccine (dpeaa)DE-He213 Clinical protocols (dpeaa)DE-He213 Follow-up studies (dpeaa)DE-He213 Patient compliance (dpeaa)DE-He213 Urinary bladder neoplasm (dpeaa)DE-He213 Raja, Anand (orcid)0000-0002-2585-8527 aut Ravishankar, Lalgudi Subramaniam aut Narayanaswamy, Kathiresan aut Radhakrishnan, Venkatraman aut Sagar, Tenali Gnana aut Enthalten in Indian Journal of Surgical Oncology Springer-Verlag, 2010 12(2021), 4 vom: 09. Sept., Seite 796-801 (DE-627)SPR030797241 nnns volume:12 year:2021 number:4 day:09 month:09 pages:796-801 https://dx.doi.org/10.1007/s13193-021-01439-w lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 12 2021 4 09 09 796-801 |
| allfieldsSound |
10.1007/s13193-021-01439-w doi (DE-627)SPR045990077 (SPR)s13193-021-01439-w-e DE-627 ger DE-627 rakwb eng Malik, Kanuj verfasserin aut Intravesical Bacillus Calmette-Guerin (BCG) Therapy for Non-muscle Invasive Bladder Cancers: Long-term Results of a Modified Schedule 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Indian Association of Surgical Oncology 2021 Abstract Intravesical BCG therapy is an integral part of management of non-muscle invasive bladder cancers. Our aim is to analyze the non-muscle invasive bladder cancer patients treated at our center with a modified schedule intravesical BCG therapy. Data from patients treated at our center from 2009 to 2017 was collected from patient records and analyzed. A 6-weekly 120-mg induction course followed by 6 monthly 120 mg has been used at our institute for NMIBC. Clinicopathological and treatment variables were collected. A total of 119 patients were treated at our center with a median follow-up period of 4.18 years with the above schedule. Nearly 96% patients were able to complete induction therapy and 79% completed the maintenance therapy. The 5-year recurrence-free survival was 83%. The recurrence and progression rates were 16.8% and 4.2% respectively. About 60% of the patients suffered from side effects of BCG with 11% having class 3 or 4 toxicity. Our regimen of monthly maintenance intravesical BCG for 6 months shows good control rates with high compliance, similar to those of other contemporary series, although with higher incidence of high-grade toxicity. BCG vaccine (dpeaa)DE-He213 Clinical protocols (dpeaa)DE-He213 Follow-up studies (dpeaa)DE-He213 Patient compliance (dpeaa)DE-He213 Urinary bladder neoplasm (dpeaa)DE-He213 Raja, Anand (orcid)0000-0002-2585-8527 aut Ravishankar, Lalgudi Subramaniam aut Narayanaswamy, Kathiresan aut Radhakrishnan, Venkatraman aut Sagar, Tenali Gnana aut Enthalten in Indian Journal of Surgical Oncology Springer-Verlag, 2010 12(2021), 4 vom: 09. Sept., Seite 796-801 (DE-627)SPR030797241 nnns volume:12 year:2021 number:4 day:09 month:09 pages:796-801 https://dx.doi.org/10.1007/s13193-021-01439-w lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 12 2021 4 09 09 796-801 |
| language |
English |
| source |
Enthalten in Indian Journal of Surgical Oncology 12(2021), 4 vom: 09. Sept., Seite 796-801 volume:12 year:2021 number:4 day:09 month:09 pages:796-801 |
| sourceStr |
Enthalten in Indian Journal of Surgical Oncology 12(2021), 4 vom: 09. Sept., Seite 796-801 volume:12 year:2021 number:4 day:09 month:09 pages:796-801 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
BCG vaccine Clinical protocols Follow-up studies Patient compliance Urinary bladder neoplasm |
| isfreeaccess_bool |
false |
| container_title |
Indian Journal of Surgical Oncology |
| authorswithroles_txt_mv |
Malik, Kanuj @@aut@@ Raja, Anand @@aut@@ Ravishankar, Lalgudi Subramaniam @@aut@@ Narayanaswamy, Kathiresan @@aut@@ Radhakrishnan, Venkatraman @@aut@@ Sagar, Tenali Gnana @@aut@@ |
| publishDateDaySort_date |
2021-09-09T00:00:00Z |
| hierarchy_top_id |
SPR030797241 |
| id |
SPR045990077 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR045990077</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230507084325.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220119s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13193-021-01439-w</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR045990077</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13193-021-01439-w-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Malik, Kanuj</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Intravesical Bacillus Calmette-Guerin (BCG) Therapy for Non-muscle Invasive Bladder Cancers: Long-term Results of a Modified Schedule</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Indian Association of Surgical Oncology 2021</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Intravesical BCG therapy is an integral part of management of non-muscle invasive bladder cancers. Our aim is to analyze the non-muscle invasive bladder cancer patients treated at our center with a modified schedule intravesical BCG therapy. Data from patients treated at our center from 2009 to 2017 was collected from patient records and analyzed. A 6-weekly 120-mg induction course followed by 6 monthly 120 mg has been used at our institute for NMIBC. Clinicopathological and treatment variables were collected. A total of 119 patients were treated at our center with a median follow-up period of 4.18 years with the above schedule. Nearly 96% patients were able to complete induction therapy and 79% completed the maintenance therapy. The 5-year recurrence-free survival was 83%. The recurrence and progression rates were 16.8% and 4.2% respectively. About 60% of the patients suffered from side effects of BCG with 11% having class 3 or 4 toxicity. Our regimen of monthly maintenance intravesical BCG for 6 months shows good control rates with high compliance, similar to those of other contemporary series, although with higher incidence of high-grade toxicity.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">BCG vaccine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Clinical protocols</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Follow-up studies</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Patient compliance</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Urinary bladder neoplasm</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Raja, Anand</subfield><subfield code="0">(orcid)0000-0002-2585-8527</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ravishankar, Lalgudi Subramaniam</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Narayanaswamy, Kathiresan</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Radhakrishnan, Venkatraman</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sagar, Tenali Gnana</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Indian Journal of Surgical Oncology</subfield><subfield code="d">Springer-Verlag, 2010</subfield><subfield code="g">12(2021), 4 vom: 09. Sept., Seite 796-801</subfield><subfield code="w">(DE-627)SPR030797241</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:4</subfield><subfield code="g">day:09</subfield><subfield code="g">month:09</subfield><subfield code="g">pages:796-801</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13193-021-01439-w</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2021</subfield><subfield code="e">4</subfield><subfield code="b">09</subfield><subfield code="c">09</subfield><subfield code="h">796-801</subfield></datafield></record></collection>
|
| author |
Malik, Kanuj |
| spellingShingle |
Malik, Kanuj misc BCG vaccine misc Clinical protocols misc Follow-up studies misc Patient compliance misc Urinary bladder neoplasm Intravesical Bacillus Calmette-Guerin (BCG) Therapy for Non-muscle Invasive Bladder Cancers: Long-term Results of a Modified Schedule |
| authorStr |
Malik, Kanuj |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)SPR030797241 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
Intravesical Bacillus Calmette-Guerin (BCG) Therapy for Non-muscle Invasive Bladder Cancers: Long-term Results of a Modified Schedule BCG vaccine (dpeaa)DE-He213 Clinical protocols (dpeaa)DE-He213 Follow-up studies (dpeaa)DE-He213 Patient compliance (dpeaa)DE-He213 Urinary bladder neoplasm (dpeaa)DE-He213 |
| topic |
misc BCG vaccine misc Clinical protocols misc Follow-up studies misc Patient compliance misc Urinary bladder neoplasm |
| topic_unstemmed |
misc BCG vaccine misc Clinical protocols misc Follow-up studies misc Patient compliance misc Urinary bladder neoplasm |
| topic_browse |
misc BCG vaccine misc Clinical protocols misc Follow-up studies misc Patient compliance misc Urinary bladder neoplasm |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Indian Journal of Surgical Oncology |
| hierarchy_parent_id |
SPR030797241 |
| hierarchy_top_title |
Indian Journal of Surgical Oncology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)SPR030797241 |
| title |
Intravesical Bacillus Calmette-Guerin (BCG) Therapy for Non-muscle Invasive Bladder Cancers: Long-term Results of a Modified Schedule |
| ctrlnum |
(DE-627)SPR045990077 (SPR)s13193-021-01439-w-e |
| title_full |
Intravesical Bacillus Calmette-Guerin (BCG) Therapy for Non-muscle Invasive Bladder Cancers: Long-term Results of a Modified Schedule |
| author_sort |
Malik, Kanuj |
| journal |
Indian Journal of Surgical Oncology |
| journalStr |
Indian Journal of Surgical Oncology |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
txt |
| container_start_page |
796 |
| author_browse |
Malik, Kanuj Raja, Anand Ravishankar, Lalgudi Subramaniam Narayanaswamy, Kathiresan Radhakrishnan, Venkatraman Sagar, Tenali Gnana |
| container_volume |
12 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Malik, Kanuj |
| doi_str_mv |
10.1007/s13193-021-01439-w |
| normlink |
(ORCID)0000-0002-2585-8527 |
| normlink_prefix_str_mv |
(orcid)0000-0002-2585-8527 |
| title_sort |
intravesical bacillus calmette-guerin (bcg) therapy for non-muscle invasive bladder cancers: long-term results of a modified schedule |
| title_auth |
Intravesical Bacillus Calmette-Guerin (BCG) Therapy for Non-muscle Invasive Bladder Cancers: Long-term Results of a Modified Schedule |
| abstract |
Abstract Intravesical BCG therapy is an integral part of management of non-muscle invasive bladder cancers. Our aim is to analyze the non-muscle invasive bladder cancer patients treated at our center with a modified schedule intravesical BCG therapy. Data from patients treated at our center from 2009 to 2017 was collected from patient records and analyzed. A 6-weekly 120-mg induction course followed by 6 monthly 120 mg has been used at our institute for NMIBC. Clinicopathological and treatment variables were collected. A total of 119 patients were treated at our center with a median follow-up period of 4.18 years with the above schedule. Nearly 96% patients were able to complete induction therapy and 79% completed the maintenance therapy. The 5-year recurrence-free survival was 83%. The recurrence and progression rates were 16.8% and 4.2% respectively. About 60% of the patients suffered from side effects of BCG with 11% having class 3 or 4 toxicity. Our regimen of monthly maintenance intravesical BCG for 6 months shows good control rates with high compliance, similar to those of other contemporary series, although with higher incidence of high-grade toxicity. © Indian Association of Surgical Oncology 2021 |
| abstractGer |
Abstract Intravesical BCG therapy is an integral part of management of non-muscle invasive bladder cancers. Our aim is to analyze the non-muscle invasive bladder cancer patients treated at our center with a modified schedule intravesical BCG therapy. Data from patients treated at our center from 2009 to 2017 was collected from patient records and analyzed. A 6-weekly 120-mg induction course followed by 6 monthly 120 mg has been used at our institute for NMIBC. Clinicopathological and treatment variables were collected. A total of 119 patients were treated at our center with a median follow-up period of 4.18 years with the above schedule. Nearly 96% patients were able to complete induction therapy and 79% completed the maintenance therapy. The 5-year recurrence-free survival was 83%. The recurrence and progression rates were 16.8% and 4.2% respectively. About 60% of the patients suffered from side effects of BCG with 11% having class 3 or 4 toxicity. Our regimen of monthly maintenance intravesical BCG for 6 months shows good control rates with high compliance, similar to those of other contemporary series, although with higher incidence of high-grade toxicity. © Indian Association of Surgical Oncology 2021 |
| abstract_unstemmed |
Abstract Intravesical BCG therapy is an integral part of management of non-muscle invasive bladder cancers. Our aim is to analyze the non-muscle invasive bladder cancer patients treated at our center with a modified schedule intravesical BCG therapy. Data from patients treated at our center from 2009 to 2017 was collected from patient records and analyzed. A 6-weekly 120-mg induction course followed by 6 monthly 120 mg has been used at our institute for NMIBC. Clinicopathological and treatment variables were collected. A total of 119 patients were treated at our center with a median follow-up period of 4.18 years with the above schedule. Nearly 96% patients were able to complete induction therapy and 79% completed the maintenance therapy. The 5-year recurrence-free survival was 83%. The recurrence and progression rates were 16.8% and 4.2% respectively. About 60% of the patients suffered from side effects of BCG with 11% having class 3 or 4 toxicity. Our regimen of monthly maintenance intravesical BCG for 6 months shows good control rates with high compliance, similar to those of other contemporary series, although with higher incidence of high-grade toxicity. © Indian Association of Surgical Oncology 2021 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER |
| container_issue |
4 |
| title_short |
Intravesical Bacillus Calmette-Guerin (BCG) Therapy for Non-muscle Invasive Bladder Cancers: Long-term Results of a Modified Schedule |
| url |
https://dx.doi.org/10.1007/s13193-021-01439-w |
| remote_bool |
true |
| author2 |
Raja, Anand Ravishankar, Lalgudi Subramaniam Narayanaswamy, Kathiresan Radhakrishnan, Venkatraman Sagar, Tenali Gnana |
| author2Str |
Raja, Anand Ravishankar, Lalgudi Subramaniam Narayanaswamy, Kathiresan Radhakrishnan, Venkatraman Sagar, Tenali Gnana |
| ppnlink |
SPR030797241 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s13193-021-01439-w |
| up_date |
2024-07-03T19:37:02.875Z |
| _version_ |
1803587863577624576 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR045990077</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230507084325.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220119s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13193-021-01439-w</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR045990077</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13193-021-01439-w-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Malik, Kanuj</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Intravesical Bacillus Calmette-Guerin (BCG) Therapy for Non-muscle Invasive Bladder Cancers: Long-term Results of a Modified Schedule</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Indian Association of Surgical Oncology 2021</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Intravesical BCG therapy is an integral part of management of non-muscle invasive bladder cancers. Our aim is to analyze the non-muscle invasive bladder cancer patients treated at our center with a modified schedule intravesical BCG therapy. Data from patients treated at our center from 2009 to 2017 was collected from patient records and analyzed. A 6-weekly 120-mg induction course followed by 6 monthly 120 mg has been used at our institute for NMIBC. Clinicopathological and treatment variables were collected. A total of 119 patients were treated at our center with a median follow-up period of 4.18 years with the above schedule. Nearly 96% patients were able to complete induction therapy and 79% completed the maintenance therapy. The 5-year recurrence-free survival was 83%. The recurrence and progression rates were 16.8% and 4.2% respectively. About 60% of the patients suffered from side effects of BCG with 11% having class 3 or 4 toxicity. Our regimen of monthly maintenance intravesical BCG for 6 months shows good control rates with high compliance, similar to those of other contemporary series, although with higher incidence of high-grade toxicity.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">BCG vaccine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Clinical protocols</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Follow-up studies</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Patient compliance</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Urinary bladder neoplasm</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Raja, Anand</subfield><subfield code="0">(orcid)0000-0002-2585-8527</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ravishankar, Lalgudi Subramaniam</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Narayanaswamy, Kathiresan</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Radhakrishnan, Venkatraman</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sagar, Tenali Gnana</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Indian Journal of Surgical Oncology</subfield><subfield code="d">Springer-Verlag, 2010</subfield><subfield code="g">12(2021), 4 vom: 09. Sept., Seite 796-801</subfield><subfield code="w">(DE-627)SPR030797241</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:4</subfield><subfield code="g">day:09</subfield><subfield code="g">month:09</subfield><subfield code="g">pages:796-801</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13193-021-01439-w</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2021</subfield><subfield code="e">4</subfield><subfield code="b">09</subfield><subfield code="c">09</subfield><subfield code="h">796-801</subfield></datafield></record></collection>
|
| score |
7.402669 |